Translational Oncology 67 (2026) 102742

Contents lists available at ScienceDirect

Translational Oncology

journal homepage: www.elsevier.com/locate/tranon

Single-cell inflammatory signaling defines a novel CEP135^{+} endothelial subtype associated with glioma progression

Ziteng Ji [a], Ulf Dietrich Kahlert [b], Sijie Wu [c], Claudia A Dumitru [d], Erol Sandalcioglu [d], Jidong Zhang [a], Dacheng Wang [a], Jingfeng Qu [a], Wenjie Shi [b,c,*], Bingchao Yan [a,*]

[a] Department of Neurosurgery, The Affiliated Xuzhou Municipal Hospital of Xuzhou Medical University, Xuzhou, China
[b] Molecular and Experimental Surgery, Clinic for General-, Visceral -, Vascular- and Transplantation Surgery, Medical Faculty and University Hospital Magdeburg, Otto-von-Guericke University, Magdeburg, Germany
[c] Department of Breast Surgery, Guilin Municipal Hospital of Traditional Chinese Medicine, China, Guilin, 541002, GuangXi, China
[d] Department of Neurosurgery, Otto-von-Guericke-University Magdeburg, 39120 Magdeburg, Germany

ARTICLE INFO

Keywords:
Inflammatory
Glioma
CEP135
Endothelial
Progression

ABSTRACT

Background: Chronic inflammation is a key driver of glioma progression, but its cellular organization within the tumor microenvironment remains poorly understood.
Methods: This study employed an integrated multi-omics analysis strategy, combining bulk transcriptomics, proteomics, and glioma cell line expression data with single-cell RNA sequencing data from paired gliomas and adjacent normal brain tissues. Inflammatory signaling activity was quantitatively assessed using pathway-level scoring methods, endothelial cell heterogeneity was analyzed at single-cell resolution, and pseudo-temporal trajectory analysis and cell-cell communication analysis were further conducted. Immunohistochemical analysis was performed using human glioma brain tissue samples from our center to independently validate key findings at the protein level.
Results: Bulk transcriptomics analysis revealed significantly activated inflammatory signals in glioblastomas. Single-cell analysis identified a highly inflammatory endothelial cell subtype that was significantly enriched in tumor tissues. Cell communication analysis further revealed enhanced signal output capabilities and participation in neurally-related ligand-receptor interactions. CEP135 was specifically enriched in this endothelial cell subtype and showed consistent upregulation of both transcriptional and protein levels across multiple independent datasets. Immunohistochemical analysis of glioma brain tissue from our center confirmed that CEP135 is primarily localized in tumor-associated endothelial regions, and its expression level was significantly correlated with increasing tumor grade.High CEP135 expression was associated with poor treatment response, shorter survival outcomes.
Conclusion: This study identified a innovative CEP135+inflammation-associated endothelial cell subtype and established CEP135 as a key biomarker linking endothelial inflammation reprogramming, tumor progression, and adverse clinical outcomes.

Introduction

Glioblastoma (GBM) is the most aggressive and lethal primary malignant tumor of the central nervous system, accounting for approximately 15% of all primary central nervous system tumors and nearly half of all malignant primary brain tumors. The age-adjusted annual incidence rate of GBM is about 3.2 cases per 100,000 individuals in the United States and other high-income countries, with a higher incidence in males and older adults [1]. Despite its relative rarity, the disease carries a disproportionately high mortality burden, with a median overall survival after diagnosis of approximately 12 to 15 months even with standard multimodal therapy (surgical resection, radiotherapy, and temozolomide), and five-year survival rates persistently below 10% [2]. These features underscore both the significant public health impact of GBM and the urgent need for a deeper mechanistic understanding of its complex biology and microenvironmental interactions to inform more effective therapeutic strategies.

Increasing evidence supports the concept that chronic, non-resolving

* Corresponding authors.
E-mail addresses: wenjie.shi@uol.de (W. Shi), ybc1984115@163.com (B. Yan).

https://doi.org/10.1016/j.tranon.2026.102742
Received 22 January 2026; Received in revised form 6 March 2026; Accepted 16 March 2026

inflammation is not only a feature of many diseases but also a central enabling condition for tumor development and progression [3,4]. These inflammatory cues shape the tumor microenvironment (TME) through cytokines and chemokines, inflammatory transcriptional circuits, and reciprocal interactions among malignant, immune, and stromal cells [5]. In addition, chronic inflammation can promote malignant cell survival and proliferation, foster angiogenesis, remodel tissue architecture, dampen effective antitumor immunity, and alter responsiveness to systemic therapies, making tumor-promoting inflammation a widely recognized enabling characteristic in cancer biology [6]. For example, genetic and pharmacological studies in mouse models of colitis-associated cancer demonstrated that persistent activation of inflammatory pathways such as NF-κB in epithelial and myeloid cells is sufficient to drive tumor initiation and growth by promoting survival signals and genomic instability [7]. Similarly, mechanistic studies have shown that chronic production of inflammatory cytokines, including interleukin-6 and tumor necrosis factor, can sustain STAT3 signaling in premalignant and malignant cells, thereby enhancing proliferation, stem-like properties, and resistance to apoptosis [8]. In glioma, chronic inflammation is increasingly recognized as an active driver of tumor progression rather than a secondary consequence of tissue injury. Experimental studies have shown that constitutive activation of inflammatory pathways such as IL-6/JAK/STAT3 and NF-κB promotes glioma cell survival, proliferation, stem-like properties, and resistance to radiotherapy and chemotherapy [9,10]. In parallel, inflammation-associated microglia and infiltrating macrophages have been shown to adopt tumor-supportive phenotypes, secreting cytokines and growth factors that enhance angiogenesis, remodel the extracellular matrix, and suppress antitumor immunity [11,12]. Together, these findings indicate that chronic inflammation organizes both tumor-intrinsic and microenvironmental programs that support glioma progression.

Despite these advances, important gaps remain in our understanding of inflammation in glioma. Most existing studies have focused either on bulk inflammatory signatures or on immune-centric mechanisms, which lack the resolution to disentangle the cellular sources, functional states, and dynamic organization of chronic inflammatory signaling within the glioma microenvironment [13,14]. In particular, the absence of robust markers linking inflammation-related stromal programs to clinical outcomes has limited the translational relevance of inflammation-focused studies in glioma.

To address these gaps, we designed an integrative, multi-omics study to systematically characterize inflammation-associated cellular programs in glioma at single-cell resolution. By integrating bulk transcriptomic data with single-cell RNA sequencing from paired tumor and normal brain samples, we sought to delineate the cellular sources and states underlying chronic inflammatory signaling in glioma. We further applied pathway-level inflammatory scoring and cell-state–specific analyses to characterize inflammation-associated stromal programs, with particular attention to non-immune compartments. Cross-platform validation and clinical correlation analyses were then used to evaluate the potential translational relevance of inflammation-linked stromal markers.

Materials and methods

Data collection and preprocessing

A total of six datasets were integrated in this study, including five public cohorts and one in-house validation cohort(**Ethics Committee approval number:XYY11 [2025] 147**). Bulk transcriptomic data of glioma were obtained from the Gene Expression Omnibus (GEO, GSE16011) and The Cancer Genome Atlas (TCGA-GBM). Proteomic data were retrieved from the Clinical Proteomic Tumor Analysis Consortium (CPTAC). Gene expression data of glioma cell lines were obtained from the Cancer Cell Line Encyclopedia (CCLE). Single-cell RNA sequencing (scRNA-seq) data were obtained from the GSE174554 dataset. Independent protein-level validation was performed using immunohistochemistry (IHC) data from the pathology center of our hospital. Inclusion criteria included histopathologically confirmed GBM, availability of matched adjacent normal tissues, and complete clinicopathological information. Patients who received neoadjuvant therapy were excluded to avoid treatment related bias. For GSE174554, raw scRNA-seq data from paired glioma and adjacent normal brain tissues were processed. After stringent single-cell quality control, we retained only those paired samples in which both the tumor tissue and the matched normal/adjacent tissue passed filtering criteria and met the minimum cell number threshold after QC. Paired samples that did not satisfy these criteria were excluded. Ultimately, 10 pairs were retained for downstream analyses.

Bulk RNA-seq data from TCGA and GEO were normalized and log2-transformed prior to analysis. Microarray datasets were background-corrected and quantile-normalized using the limma package. Genes with counts per million (CPM) < 1 in $>80\%$ of samples were defined as lowly expressed and excluded from downstream analyses. CPTAC proteomic data were median-centered and log2-transformed. CCLE expression profiles were normalized to transcripts per million (TPM). Inflammatory signaling activity was assessed using the Hallmark Inflammatory Response gene set obtained from the Molecular Signatures Database (https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HALLMARK_INFLAMMATORY_RESPONSE.html).

Single-cell RNA-seq data processing

Single-cell transcriptomic data were processed using the Seurat (v4.0) R package. Low-quality cells and technical artifacts were removed prior to downstream analyses. Specifically, cells expressing fewer than 200 genes were excluded to remove empty droplets or dying cells; cells with >15,000 detected transcripts were removed to avoid doublets or multiplets; and cells with mitochondrial gene percentages exceeding 20% were excluded to eliminate stressed or apoptotic cells.

After quality control, gene expression values were normalized using Seurat's NormalizeData function, which scales each cell by total expression and performs log transformation. The vst method was used to identify 1500 highly variable genes, which capture the major sources of cellular heterogeneity. The data were then scaled, and principal component analysis (PCA) was performed using the highly variable genes to reduce dimensionality and capture biological variation.

To correct for inter-patient batch effects, Harmony was applied in the PCA space. The top 10 Harmony-corrected principal components were used to construct a shared nearest neighbor graph. Cells were visualized using t-SNE, and clustering was performed using the FindClusters function with a resolution of 0.4. Cell clusters were annotated based on canonical marker genes, and subtype-specific marker genes were identified using FindAllMarkers with min.pct $= 0.1$, logfc.threshold $= 0.1$, and $P < 0.05$.

Identification of malignant and non-malignant epithelial cells

To distinguish malignant from non-malignant epithelial cells at single-cell resolution, copy number variation (CNV) analysis was performed using CopyKAT. CopyKAT infers large-scale chromosomal gains and losses from scRNA-seq expression profiles by integrating Bayesian hierarchical modeling with Gaussian mixture modeling.

Gene expression matrices of all epithelial cells were used as input. High-confidence diploid cells were first identified as a reference population. Hierarchical clustering was then applied to classify cells with significant CNV patterns indicative of genomic instability. Cells exhibiting widespread aneuploidy were classified as malignant, whereas cells with diploid or near-diploid genomes were classified as non-malignant. This approach enabled robust discrimination between tumor-derived and normal or reactive epithelial cells in the glioma microenvironment.

Endothelial cell subclustering and inflammatory signature scoring

To systematically characterize endothelial heterogeneity, endothelial cells were extracted from the full scRNA-seq dataset based on canonical endothelial markers, including PECAM1, VWF, and EMCN. The extracted endothelial cells were reprocessed using the standard Seurat workflow, including normalization, identification of highly variable genes, PCA, and Harmony-based batch correction. Cells were then reclustered using a shared nearest neighbor (SNN) graph and visualized by t-SNE to identify transcriptionally distinct endothelial subtypes.

To define subtype-specific transcriptional programs, marker genes for each endothelial subtype were identified using Seurat's FindAllMarkers function, and representative markers were visualized to compare molecular features across subtypes. To quantify inflammatory signaling activity, GSVA was performed at the single-cell level using the Hallmark Inflammatory Response gene set, assigning each cell an inflammatory pathway score that was compared across endothelial subclusters.

In addition, an inflammation-related gene signature was constructed based on this gene set, and AUCell was used to calculate the area under the curve (AUC) for each cell, reflecting the degree of signature enrichment. AUC heatmaps were used to visualize the distribution of inflammatory activity across endothelial subtypes, and boxplots were used to compare AUC values between subtypes, thereby quantitatively defining the inflammatory endothelial state.

Pseudotime trajectory analysis

To investigate dynamic endothelial reprogramming during glioma progression, pseudotime trajectory analysis was performed using Monocle2. Raw count matrices of endothelial subclusters were used to construct CellDataSet objects, and differentially expressed genes between tumor and normal endothelial cells were selected as ordering genes. Dimensionality reduction was performed using the DDRTree algorithm to reconstruct a low-dimensional manifold representing cell-state transitions. Cells were ordered along pseudotime and visualized to identify transitional and terminal endothelial states.

Cell–cell communication analysis

To systematically analyze intercellular communication in the glioma microenvironment, CellChat was used to infer ligand–receptor interactions from scRNA-seq data. Seurat-annotated cell identities and expression matrices were imported into CellChat, and the CellChatDB. human ligand–receptor database was applied. By identifying ligand–receptor pairs co-expressed in sender and receiver cells above defined thresholds, CellChat computed communication probabilities and inferred cell group–level signaling networks.

To quantify communication capacity, Outgoing interaction strength and Incoming interaction strength were calculated for each cell group. Outgoing interaction strength was defined as the sum of communication probabilities from a given cell group to all target groups, whereas Incoming interaction strength was defined as the sum of probabilities received from all source groups. These metrics were used to assess the overall signaling output and input of each cell population.

To evaluate the complexity of communication, the Number of interactions was defined as the number of statistically significant ligand–receptor pairs between each pair of cell groups. Finally, to specifically characterize the inflammatory endothelial subtype EC0, significantly enriched ligand–receptor interaction axes between EC0 and other tumor microenvironment cell populations were identified using differential communication analysis and visualized to reveal key signaling pathways involving EC0.

Clinical correlation and survival analysis

Clinical data were downloaded from public databases and matched with gene expression profiles using unique patient identifiers. Samples with missing survival information, follow-up time <30 days, or incomplete key clinic pathological variables were excluded. Patients with available CEP135 expression data and complete clinical annotations were included in downstream analyses. Clinical variables analyzed in this study included age, gender, race, WHO tumor grade, primary therapy outcome, and 1p/19q codeletion status.

CEP135 expression levels were extracted from normalized TCGA RNA-seq data. Patients were stratified into high- and low-expression groups based on the median CEP135 expression value. Comparisons of CEP135 expression across clinical subgroups were performed using the Wilcoxon rank-sum test for two-group comparisons or the Kruskal–Wallis test for comparisons involving more than two groups.

Survival analyses were conducted to evaluate the prognostic significance of CEP135. Overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI) were analyzed using the Kaplan–Meier method, and differences between expression groups were assessed by the log-rank test. Hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) were estimated using univariate Cox proportional hazards regression models. Statistical analyses were performed using R software, and a two-sided P value < 0.05 was considered statistically significant.

Drug sensitivity prediction analysis

To predict drug sensitivity, gene expression profiles were input into the pRRophetic algorithm to estimate the half-maximal inhibitory concentration (IC50) values for multiple therapeutic agents, including AUY922, Bicalutamide, Mitomycin C, Roscovitine, Sunitinib, and 17-AAG. The prediction model was trained using pharmacogenomic data from the Genomics of Drug Sensitivity in Cancer (GDSC) database. Patients were stratified into high and low expression groups according to CEP135 expression levels, using the median value as the cutoff. The Wilcoxon rank-sum test was applied to compare predicted IC50 values between the two groups.

Results

Bulk transcriptomic profiling reveals global inflammatory activation in glioblastoma

To explore the potential biological role of inflammatory mediators in tumor progression, we first evaluated inflammatory signaling activity using the Hallmark Inflammatory Response gene set. Bulk transcriptomic profiling of glioblastoma (GBM) and normal brain tissues from the GSE16011 cohort revealed a clear molecular separation between tumor and normal samples, as shown by principal component analysis (PCA) (Fig. 1A). Differential expression analysis identified a large number of genes significantly dysregulated in GBM compared with normal brain (Fig. 1B), with representative upregulated and downregulated genes illustrated in the heatmap (Fig. 1C).

Gene set enrichment analysis demonstrated a strong enrichment of the Hallmark Inflammatory Response pathway in GBM (Fig. 1D), indicating that inflammatory signaling is globally activated in glioma. Consistently, GSVA scores for the inflammatory response gene set were significantly higher in tumor samples compared with normal brain (Fig. 1E) and increased progressively with tumor grade (WHO II-IV) (Fig. 1F). These results indicate that inflammation is a hallmark of glioma progression at the bulk transcriptomic level.



Fig. 1. Bulk transcriptomic profiling of glioblastoma (GBM) and normal brain samples from the GSE16011 cohort.
(A) PCA plot showing separation of normal and tumor samples.
(B) Volcano plot of differential gene expression between tumor and normal samples (Up/Down/Not significant).
(C) Heatmap of the top 10 upregulated and top 10 downregulated differentially expressed genes (DEGs) in tumor versus normal samples.
(D) GSEA enrichment plot demonstrating significant enrichment of the Inflammatory Response pathway in GBM.
(E) GSVA scores of the Hallmark Inflammatory Response gene set comparing normal and tumor groups.
(F) Association between Hallmark Inflammatory Response GSVA scores and tumor grade stage (II-IV).

Single-cell atlas reveals major cellular components of the glioma microenvironment

To resolve the cellular origin of inflammatory signaling, we constructed a single-cell transcriptomic atlas of paired normal brain and glioma tissues. t-SNE visualization revealed distinct cell populations in normal and tumor samples (Fig. 2A-B), including malignant cells, immune cells, stromal cells, and endothelial cells. Tumor tissues showed a marked reshaping of cellular composition, with expansion of tumor and stromal compartments and altered immune cell proportions (Fig. 2C-D).

Canonical marker genes were used to annotate each cluster (Fig. 2E), and their relative expression levels across cell types were summarized (Fig. 2F). This atlas provided a high-resolution map of the glioma microenvironment, enabling downstream identification of cell-type-specific inflammatory states.

Aneuploidy-based inference identifies malignant cells with elevated inflammatory activity

Using CopyKAT, we inferred chromosomal copy number variations at the single-cell level to distinguish malignant from non-malignant cells. Tumor samples showed a marked increase in aneuploid cells compared with normal brain, whereas most normal cells were diploid (Supplement Figure 1A). These populations were visualized on the t-SNE map (Supplement 1B).

Importantly, malignant (aneuploid) cells exhibited significantly higher inflammatory scores than diploid cells (Supplement 1C), indicating that tumor cells themselves contribute to the inflamed microenvironment in glioma.

Re-clustering of endothelial cells identifies an inflammation-high EC0 subtype

To investigate whether inflammation is also encoded in non-malignant compartments, endothelial cells were extracted and re-clustered, revealing four transcriptionally distinct endothelial subtypes (EC0-EC3) (Fig. 3A-C). EC0 was markedly enriched in tumor samples compared with normal brain (Fig. 3D-G).

Subtype-specific marker genes further distinguished EC0 from other endothelial populations (Fig. 3H). GSVA analysis demonstrated that EC0 showed significantly elevated inflammatory signaling, including interferon responses, IL6/JAK/STAT3, and complement pathways (Fig. 3I). At the single-cell level, AUCell analysis confirmed that EC0 had the highest inflammatory AUC scores among all endothelial subtypes (Fig. 3J-K), defining EC0 as an inflammation-high endothelial state.

Trajectory and communication analyses reveal dynamic EC0 reprogramming and enhanced neural-associated signaling

Trajectory inference revealed that endothelial cells undergo continuous state transitions, with EC0 occupying an intermediate-to-late pseudotime position, suggesting that EC0 represents a dynamically induced state during tumor progression rather than a pre-existing lineage (Fig. 4A-C). Genes and gene modules showed coordinated expression changes along pseudotime, consistent with progressive inflammatory and functional remodeling of endothelial cells (Fig. 4D).

Cell-cell communication analysis further showed that EC0 exhibited strong outgoing signaling activity within the tumor microenvironment (Fig. 4E) and formed an increased number of ligand-receptor interactions with other cell types (Fig. 4F). Notably, EC0 displayed enriched neural-associated signaling, including NRXN—NLGN and NRG-ERBB axes (Fig. 4G), indicating that this inflammatory endothelial state integrates vascular, immune, and neural communication.

CEP135 is specifically enriched in inflammation-associated endothelial cells and validated across multiple platforms

Among EC0-specific genes, CEP135 emerged as a highly selective marker. CEP135 mRNA expression was significantly elevated in GBM compared with normal brain in TCGA (Fig. 5A) and showed concordant



Fig. 2. Single-cell transcriptomic landscape of normal brain and glioblastoma tissues.
(A) tSNE visualization of annotated cell types in normal samples.
(B) tSNE visualization of annotated cell types in tumor samples.
(C) Cell-type composition (proportion) in normal versus tumor groups.
(D) Comparison of cell-type proportions between normal and tumor samples.
(E) Heatmap showing canonical marker genes used for cell-type annotation across clusters.
(F) Dot/strip plot summarizing average log2 fold-change of marker genes across annotated cell populations.

protein-level upregulation in CPTAC (Fig. 5B). CEP135 was also highly expressed in glioma-related cell lines from the CCLE database (Fig. 5C). Immunohistochemical staining confirmed strong CEP135 expression in tumor-associated endothelial regions and progressive upregulation with increasing WHO grade (Fig. 5D), validating CEP135 as a marker of the inflammatory endothelial state in human gliomas.

CEP135 expression correlates with clinical features and poor prognosis

CEP135 expression showed significant associations with patient gender, age, and race (Fig. 6A-C), as well as with 1p/19q codeletion status (Fig. 6D). CEP135 was significantly higher in high-grade gliomas (WHO grade 4) compared with lower-grade tumors (Fig. 6E) and in patients with poor response to primary therapy (Fig. 6F).

Survival analyses demonstrated that patients with high CEP135 expression had significantly worse overall survival, disease-specific survival, and progression-free interval compared with low-expression groups (Fig. 6G-I), indicating that the CEP135^{+} inflammatory endothelial state has strong prognostic relevance in glioma.

CEP135 expression is associated with differential drug sensitivity

To explore the potential therapeutic implications of CEP135 expression, we performed drug sensitivity prediction analysis based on transcriptomic data. Patients in the High CEP135 group exhibited significantly lower predicted IC50 values for HSP90 inhibitors (AUY922



Fig. 3. *Re*-clustering of endothelial cells identifies four endothelial subtypes and reveals an inflammation-high EC0 population.
(A-C) tSNE plots showing endothelial subtypes (EC0-EC3) and their distribution.
(D) Proportion of endothelial subtypes in normal versus tumor samples.
(E-F) Cell numbers of each endothelial subtype in normal (E) and tumor (F) samples.
(G) Comparison of subtype proportions between normal and tumor groups.
(H) Heatmap showing subtype-specific marker genes across EC0-EC3.
(I) Differential GSVA pathway activity across endothelial subtypes, highlighting inflammatory signaling enrichment in EC0.
(J) AUCell projection illustrating single-cell level activity (AUC) of an inflammation-related gene set across endothelial cells.
(K) Boxplot comparing inflammation-related AUCell AUC scores among EC subtypes.

and 17-AAG), suggesting enhanced sensitivity to HSP90 targeted therapy. In contrast, differential sensitivity patterns were also observed for Mitomycin C and Sunitinib, indicating potential variability in response to DNA damaging agents and tyrosine kinase inhibitors. Notably, CEP135 high tumors demonstrated distinct sensitivity patterns across multiple therapeutic classes, implying that CEP135 expression may influence treatment vulnerability and could serve as a biomarker for therapeutic stratification**(Supplement Figure 2)**.

Discussion

Chronic inflammatory signaling has long been recognized as a hallmark of glioma and has been implicated in tumor progression, immune suppression, and therapeutic resistance [15,16]. At the bulk transcriptomic level, our finding that the inflammatory response pathway is strongly enriched in glioblastoma and progressively increases with tumor grade is highly consistent with previous large-scale



Fig. 4. Trajectory inference and cell-cell communication analyses characterize EC0 functional state.
(A) Trajectory plot with discrete states indicating endothelial state transitions.
(B) Trajectory topology highlighting branch structure across states.
(C) Pseudotime ordering of cells along the trajectory.
(D) Heatmap of genes/modules dynamically regulated along pseudotime.
(E) Outgoing interaction strength across cell types, highlighting EC0 communication activity within the tumor microenvironment.
(F) Heatmap of the number of inferred interactions between cell types.
(G) Dot plot of selected ligand-receptor pairs showing enhanced neural-associated signaling (e.g., NRXN—NLGN and NRG-ERBB axes) involving EC0.

transcriptomic studies of glioma [17-19]. Earlier analyses of TCGA and GEO cohorts have repeatedly reported enrichment of inflammatory and immune-related gene signatures in high-grade gliomas, including interferon signaling, cytokine-cytokine receptor interactions, and NF-κB-related pathways [17], and have linked these signatures to tumor aggressiveness and poor prognosis [18,19]. However, while prior bulk studies have established inflammation as a hallmark of glioma, they have largely treated inflammatory activation as a global tumor property without resolving its cellular origins. In this regard, our results reinforce these observations by demonstrating a clear separation between tumor and normal brain samples and by quantitatively showing a stepwise increase in inflammatory GSVA scores from WHO grade II to IV, supporting the concept that inflammation accompanies glioma progression rather than representing a binary on/off feature. To resolve the cellular sources underlying this inflammatory signaling. we next examined the glioma microenvironment at single-cell resolution. Our single-cell analysis indicates that glioma is associated with a coordinated remodeling of the TME involving malignant, stromal, immune, and endothelial compartments, rather than alterations restricted to a single lineage. This finding is broadly consistent with previous scRNA-seq studies demonstrating extensive cellular heterogeneity in glioblastoma [20,21]. However, much of the earlier work primarily emphasized malignant cell-state diversity or immune cell infiltration as the dominant features of microenvironmental change [21]. In contrast, our data highlight a concomitant expansion of tumor-associated stromal compartments together with shifts in immune cell proportions, suggesting that microenvironmental reprogramming in glioma is more global and multicellular than previously appreciated.

In parallel with tumor-intrinsic inflammatory activation, our identification of a distinct inflammation-high endothelial subtype (EC0) highlights the vascular compartment as an additional, previously underappreciated contributor to glioma-associated inflammation. For example, Vanlandewijck et al [22]. constructed a single-cell atlas of brain vasculature that highlighted endothelial zonation associated with transport and metabolic specialization, without defining inflammation as a core endothelial program. Another single-cell study by Neftel et al [20]. primarily focused on malignant cell-state heterogeneity and tumor plasticity, with endothelial cells treated as supporting populations. Our



Fig. 5. Validation of CEP135 expression at transcriptomic, proteomic, cell line, and tissue levels.
(A) CEP135 mRNA expression in normal brain versus GBM in the TCGA dataset.
(B) CEP135 protein expression (Z-value) in normal versus GBM in the CPTAC dataset.
(C) CEP135 expression across glioma-related cell lines in the CCLE database.
(D) Representative immunohistochemical (IHC) staining images showing CEP135 expression in normal brain and glioma samples across WHO grade I-IV (scale bar, 50 μm).

data refine this view by demonstrating that inflammatory programs, including interferon alpha response, inflammatory response, IL6/JAK/STAT3 signaling, and complement activation, are selectively enriched in EC0 in glioma, which supports the robustness of this inflammation-high EC0 phenotype and argues against a purely technical or transient activation state. Importantly, the enrichment of EC0 in tumor tissue suggests that endothelial inflammation is actively induced during glioma progression, rather than reflecting baseline vascular heterogeneity in the normal brain. One possible explanation for the emergence of EC0 is sustained exposure of tumor-associated endothelial cells to malignant cell-derived inflammatory cues, hypoxia, and mechanical stress within the abnormal glioma vasculature [23]. Regardless of the initiating mechanism, the presence of an inflammation-high endothelial population supports a model in which chronic inflammation in glioma is coordinated across malignant and stromal compartments.

Having established the existence of an inflammation-high endothelial state (EC0) within the glioma microenvironment, a key next question is whether this state can be anchored to a robust and clinically tractable molecular marker. Among EC0-specific genes, Centrosomal protein 135 (CEP135) emerged as a highly selective marker that consistently distinguished inflammation-associated endothelial cells across multiple datasets. Existing studies have characterized CEP135 primarily as a centrosomal protein involved in centrosome integrity and cell-cycle regulation, making its selective enrichment in inflammation-associated endothelial cells unexpected. For example, in breast cancer cells, dysregulation of CEP135 isoforms has been shown to promote centrosome amplification and genomic instability, contributing to oncogenic phenotypes such as multipolar spindles and chromosome segregation errors, underscoring its role in tumor cell biology beyond baseline centrosomal function [24]. Notably, CEP135 has not previously been linked to glioma biology or endothelial inflammation. Existing studies have characterized CEP135 primarily as a centrosomal protein involved in microtubule organization and cell-cycle regulation, making its selective enrichment in inflammation-associated endothelial cells unexpected [25,26]. This observation suggests that CEP135 may mark a specialized endothelial state adapted to chronic inflammatory, hypoxic, and structurally abnormal vascular conditions in glioma, rather than reflecting generalized endothelial activation. Clinically, the association of high CEP135 expression with adverse molecular features, higher tumor grade, poor response to primary therapy, and significantly worse survival outcomes further position it as a novel endothelial marker that links inflammation-driven vascular reprogramming to glioma progression and patient prognosis, providing a potential bridge between single-cell resolved microenvironmental heterogeneity and translational application.

In summary, we identified a novel inflammation-high endothelial cell state (EC0) in the glioma microenvironment. CEP135 serves as a key marker of this state, strongly correlating with higher tumor grade, poor therapeutic response, and worse patient survival. These findings position CEP135 as a potential prognostic biomarker linking inflammation-driven vascular changes to glioma progression. However, there are several limitations in our study. The primary focus on cross-sectional patient samples limits our ability to track the temporal dynamics of CEP135 expression during glioma progression. Additionally, while our study defines CEP135 as a key marker of the inflammatory endothelial state, the precise mechanisms through which CEP135 regulates endothelial function and its interaction with the TME remain to be fully elucidated. Future research should focus on the mechanistic role of CEP135 in endothelial inflammation and vascular remodeling in glioma, including its potential involvement in regulating angiogenesis and the blood-brain barrier. Moreover, exploring the therapeutic targeting of CEP135 in combination with immune checkpoint inhibitors or anti-angiogenic therapies may provide novel treatment strategies for glioma patients.

Data availability

All data inquiries can be directed to the corresponding author.



Fig. 6. Clinical correlations and prognostic significance of CEP135 expression.
(A-C) CEP135 expression stratified by gender (A), age (B), and race (C).
(D) CEP135 expression by 1p/19q codeletion status.
(E) CEP135 expression across WHO grades (G2&G3 vs G4).
(F) CEP135 expression by primary therapy outcome (e.g., PD/SD vs PR/CR).
(G-I) Kaplan-Meier survival analyses comparing high versus low CEP135 expression groups for overall survival (G), disease-specific survival (H), and progression-free interval.

Authors contributions

The conceptualization of the study was led by ZJ and UDK, while the methodology was developed by SW, JZ, CAD, ES and DW. JQ also conducted the formal analysis. QD was responsible for preparing the data. ZJ,UDK,WS and CAD drafted the original manuscript and, along with BY, supervised the entire project. The manuscript revisions were undertaken by ZJ and UDK, who also managed the project administration and funding acquisition alongside BY. All authors have reviewed and approved the final version of the manuscript.

Ethics statement

The study protocol was approved by the Ethics Committee of Xuzhou Municipal Hospital Affiliated to Xuzhou Medical University (Approval No XYY11[2025]147).

Funding

None.

CRediT authorship contribution statement

Ziteng Ji: Writing – review & editing, Writing – original draft, Software, Formal analysis, Data curation, Conceptualization. **Ulf Dietrich Kahlert:** Writing – review & editing, Writing – original draft, Resources, Project administration, Methodology, Investigation, Funding acquisition, Conceptualization. **Sijie Wu:** Visualization, Validation, Software, Resources, Methodology, Investigation, Data curation, Conceptualization. **Claudia A Dumitru:** Writing – original draft, Visualization, Validation, Software, Formal analysis, Data curation, Conceptualization. **Erol Sandalcioglu:** Resources, Formal analysis, Data curation, Conceptualization. **Jidong Zhang:** Validation, Software, Resources, Methodology, Formal analysis, Data curation, Conceptualization. **Dacheng Wang:** Software, Resources, Methodology, Investigation, Data curation, Conceptualization. **Jingfeng Qu:** Writing – review

& editing, Validation, Formal analysis, Data curation. **Wenjie Shi:** Writing – review & editing, Writing – original draft, Visualization, Validation, Supervision, Software, Resources, Project administration, Methodology. **Bingchao Yan:** Writing – review & editing, Writing – original draft, Software, Resources, Project administration, Methodology, Investigation, Funding acquisition, Formal analysis, Conceptualization.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

Not applicable.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.tranon.2026.102742.

References

[1] Q.T. Ostrom, M. Price, C. Neff, et al., CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015–2019, Neuro-oncol 24 (Supplement_5) (2022) v1–v95.
[2] D. Sipos, B.L. Raposa, O. Freihat, et al., Glioblastoma: clinical presentation, multidisciplinary management, and long-term outcomes, Cancers (Basel) 17 (1) (2025), https://doi.org/10.3390/cancers17010146.
[3] S.I. Grivennikov, F.R. Greten, M. Karin, Immunity, inflammation, and cancer, Cell 140 (6) (2010) 883–899.
[4] A. Mantovani, P. Allavena, A. Sica, et al., Cancer-related inflammation, nature 454 (7203) (2008) 436–444.
[5] F.R. Greten, S.I. Grivennikov, Inflammation and cancer: triggers, mechanisms, and consequences, Immunity 51 (1) (2019) 27–41.
[6] D. Hanahan, Hallmarks of cancer: new dimensions, Cancer Discov 12 (1) (2022) 31–46.
[7] F.R. Greten, L. Eckmann, T.F. Greten, et al., IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer, Cell 118 (3) (2004) 285–296.
[8] S. Grivennikov, E. Karin, J. Terzic, et al., IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer, Cancer cell 15 (2) (2009) 103–113.
[9] B.C. McFarland, S.W. Hong, R. Rajbhandari, et al., NF-κb-induced IL-6 ensures STAT3 activation and tumor aggressiveness in glioblastoma, PloS one 8 (11) (2013) e78728.
[10] A.J. West, V. Tsui, S.S. Stylli, et al., The role of interleukin-6-STAT3 signalling in glioblastoma, Oncol Lett 16 (4) (2018) 4095–4104.
[11] R.S. Andersen, A. Anand, D.S.L. Harwood, et al., Tumor-associated microglia and macrophages in the glioblastoma microenvironment and their implications for therapy, Cancers (Basel) 13 (17) (2021) 4255.
[12] J. Chen, Q. Wu, A.E. Berglund, et al., Tumor-associated macrophages in glioblastoma: mechanisms of tumor progression and therapeutic strategies, Cells 14 (18) (2025) 1458.
[13] D. Hambardzumyan, D.H. Gutmann, H. Kettenmann, The role of microglia and macrophages in glioma maintenance and progression, Nat Neurosci 19 (1) (2016) 20–27.
[14] M. Binnewies, E.W. Roberts, K. Kersten, et al., Understanding the tumor immune microenvironment (TIME) for effective therapy, Nat Med 24 (5) (2018) 541–550.
[15] N. Chen, C. Peng, D. Li, Epigenetic underpinnings of inflammation: a key to unlock the tumor microenvironment in glioblastoma, Front Immunol 13 (2022) 869307.
[16] X. Li, W. Gou, X. Zhang, Neuroinflammation in glioblastoma: progress and perspectives, Brain Sci 14 (7) (2024) 687.
[17] R.G. Verhaak, K.A. Hoadley, E. Purdom, et al., Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1, Cancer cell 17 (1) (2010) 98–110.
[18] Q. Wang, B. Hu, X. Hu, et al., Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment, Cancer cell 32 (1) (2017) 42–56.e6.
[19] M. Ceccarelli, F.P. Barthel, T.M. Malta, et al., Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma, Cell 164 (3) (2016) 550–563.
[20] C. Neftel, J. Laffy, M.G. Filbin, et al., An integrative model of cellular states, plasticity, and genetics for glioblastoma, Cell 178 (4) (2019) 835–849.e21.
[21] S. Darmanis, S.A. Sloan, D. Croote, et al., Single-cell RNA-seq analysis of infiltrating neoplastic cells at the migrating front of human glioblastoma, Cell Rep 21 (5) (2017) 1399–1410.
[22] M. Vanlandewijck, L. He, M.A. Mäe, et al., A molecular atlas of cell types and zonation in the brain vasculature, Nature 554 (7693) (2018) 475–480.
[23] R.K. Jain, E. Di Tomaso, D.G. Duda, et al., Angiogenesis in brain tumours, Nat Rev Neurosci 8 (8) (2007) 610–622.
[24] D. Ganapathi Sankaran, A.J. Stemm-Wolf, C.G. Pearson, CEP135 isoform dysregulation promotes centrosome amplification in breast cancer cells, Mol Biol Cell 30 (10) (2019) 1230–1244.
[25] M.S. Hussain, S.M. Baig, S. Neumann, et al., A truncating mutation of CEP135 causes primary microcephaly and disturbed centrosomal function, Am J Hum Genet 90 (5) (2012) 871–878.
[26] T. Ohta, R. Essner, J.-H. Ryu, et al., Characterization of Cep135, a novel coiled-coil centrosomal protein involved in microtubule organization in mammalian cells, J Cell Biol 156 (1) (2002) 87–100.